Volume 49, Issue 3 , Pages 210-216, March 2010
Implications of Extending the ADHD Age-of-Onset Criterion to Age 12: Results from a Prospectively Studied Birth Cohort
Objective
To evaluate whether including children with onset of symptoms between ages 7 and 12 years in the ADHD diagnostic category would: (a) increase the prevalence of the disorder at age 12, and (b) change the clinical and cognitive features, impairment profile, and risk factors for ADHD compared with findings in the literature based on the DSM-IV definition of the disorder.
Method
A birth cohort of 2,232 British children was prospectively evaluated at ages 7 and 12 years for ADHD using information from mothers and teachers. The prevalence of diagnosed ADHD at age 12 was evaluated with and without the inclusion of individuals who met DSM-IV age-of-onset criterion through mothers' or teachers' reports of symptoms at age 7. Children with onset of ADHD symptoms before versus after age 7 were compared on their clinical and cognitive features, impairment profile, and risk factors for ADHD.
Results
Extending the age-of-onset criterion to age 12 resulted in a negligible increase in ADHD prevalence by age 12 years of 0.1%. Children who first manifested ADHD symptoms between ages 7 and 12 did not present correlates or risk factors that were significantly different from children who manifested symptoms before age 7.
Conclusions
Results from this prospective birth cohort might suggest that adults who are able to report symptom onset by age 12 also had symptoms by age 7, even if they are not able to report them. The data suggest that the prevalence estimate, correlates and risk factors of ADHD will not be affected if the new diagnostic scheme extends the age-of-onset criterion to age 12.
Key Words: ADHD, Attention-deficit/hyperactivity disorder, Diagnostic criteria, DSM-IV, DSM-V, Age-of-onset
To access this article, please choose from the options below
This article is discussed by Dr. Russell A. Barkley in an editorial on page 205.
This research was supported by the UK Medical Research Council (G9806489, G0100527, and G0601483).
Disclosure: Dr. Polanczyk has served as a speaker for Novartis and is a recipient of a 2008 National Alliance of Research on Schizophrenia and Depression (NARSAD) Young Investigator Award. Dr. Kollins has received research support and/or consultant fees from Addrenex Pharmaceuticals, Otsuka Pharmaceuticals, Shire Pharmaceuticals, the National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), and Environmental Protection Agency (EPA). Dr. Rohde has served as a speaker and/or consultant for Eli Lilly, Janssen-Cilag, and Novartis in the last 3 years. Currently, his only industry-related activity is taking part in the advisory board/speakers' bureau for Eli Lilly and Novartis. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him have received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Abbott, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Novartis, and Shire. Dr. Houts, Caspi, and Moffitt report no biomedical financial interests or potential conflicts of interest.
PII: S0890-8567(09)00071-9
doi:10.1016/j.jaac.2009.12.014
© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Against the Status Quo: Revising the Diagnostic Criteria for ADHD
Volume 49, Issue 3 , Pages 210-216, March 2010
